Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas A Abrams

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Investigational New Drugs|January 4, 2020
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancerLipika Goyal, Surendra Pal Chaudhary, Eunice L Kwak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2013
Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II studyAndrew X Zhu, Marek Ancukiewicz, Jeffrey G Supko, et al.
Practical Radiation Oncology|June 4, 2014
Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local controlJennifer Y Wo, Stephanie K Childs, Jackie Szymonifka, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 30, 2020
Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized TrialJustin C Brown, Sui Zhang, Jennifer A Ligibel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2018
A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular CarcinomaLipika Goyal, Hui Zheng, Thomas A Abrams, et al.
The Lancet. Oncology|November 26, 2009
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 studyAndrew X Zhu, Jeffrey A Meyerhardt, Lawrence S Blaszkowsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II studyAndrew X Zhu, Dushyant V Sahani, Dan G Duda, et al.
Journal for Immunotherapy of Cancer|June 21, 2023
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humansVictoire Cardot-Ruffino, Naima Bollenrucher, Luisa Delius, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2023
PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic CancerLestat R Ali, Patrick J Lenehan, Victoire Cardot-Ruffino, et al.
Medrxiv : the Preprint Server for Health Sciences|October 17, 2024
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumabRyan J Park, Milan Parikh, Leon Pappas, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Investigational New Drugs|January 4, 2020
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancerLipika Goyal, Surendra Pal Chaudhary, Eunice L Kwak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2013
Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II studyAndrew X Zhu, Marek Ancukiewicz, Jeffrey G Supko, et al.
Practical Radiation Oncology|June 4, 2014
Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local controlJennifer Y Wo, Stephanie K Childs, Jackie Szymonifka, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 30, 2020
Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized TrialJustin C Brown, Sui Zhang, Jennifer A Ligibel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2018
A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular CarcinomaLipika Goyal, Hui Zheng, Thomas A Abrams, et al.
The Lancet. Oncology|November 26, 2009
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 studyAndrew X Zhu, Jeffrey A Meyerhardt, Lawrence S Blaszkowsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II studyAndrew X Zhu, Dushyant V Sahani, Dan G Duda, et al.
Journal for Immunotherapy of Cancer|June 21, 2023
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humansVictoire Cardot-Ruffino, Naima Bollenrucher, Luisa Delius, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2023
PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic CancerLestat R Ali, Patrick J Lenehan, Victoire Cardot-Ruffino, et al.
Medrxiv : the Preprint Server for Health Sciences|October 17, 2024
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumabRyan J Park, Milan Parikh, Leon Pappas, et al.
Pageof 5